Dec 05, 2022 8:30am EST Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
Nov 10, 2022 5:20pm EST Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Sep 06, 2022 9:00am EDT Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 24, 2022 4:05pm EDT Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase
Aug 15, 2022 4:05pm EDT Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Jun 13, 2022 9:00am EDT Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
May 16, 2022 4:05pm EDT Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Apr 25, 2022 4:50pm EDT Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Apr 21, 2022 9:00am EDT Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
